- Japanese pharma company Kisco acquires
shareholdings
Regulatory News:
SAFE ORTHOPAEDICS (Paris:SAFOR) (FR0012452746 – SAFOR), a
company specialized in the design and marketing of single-use
implants and instruments improving the minimally invasive treatment
of spinal fracture conditions, today announces that it has raised
€6.95 million from its capital increase through the issue of
new shares with preferential subscription rights for
shareholders.
“The rights issue represents a decisive step forward that will
help us to accelerate our development in the vertebral fracture
market. In particular, we are looking to strengthen our sales teams
in France, Germany and the United Kingdom,” said Pierre
Dumouchel, Chief Executive Officer of Safe Orthopaedics. “The
faster pace of our development will also be offering new minimally
invasive technologies and forming new strategic, commercial and
technology partnerships. These will be along similar lines to the
alliance we announced recently with Japanese company Kisco, a
subsidiary of the Otsuka Medical Devices group, which has today
established a stake in our share capital via the rights issue.”
The gross proceeds from the rights issue totaled €6,947,338 and
led to the issue of 17,368,345 shares at a unit price of €0.40,
corresponding to 83% of the initially offered number of shares. All
the subscription requests, both by way of right and for excess
shares, were satisfied.
Safe Orthopaedics’ post-money share capital will stand at
€4,126,802.2, divided into 41,268,022 shares, each with a nominal
value of €0.10.
Settlement-delivery and admission to trading of the new shares
on Euronext’s regulated market in Paris is due to take place on
July 6, 2018. These new shares will be immediately fungible with
Safe Orthopaedics’ existing shares already traded on Euronext
Paris and negotiable from that date on the same line as the
Company’s existing shares under ISIN code FR0012452746.
Ownership of share capital and voting rights after the rights
issue
Safe Orthopaedics’ share capital and voting rights break
down as follows:
Shareholders/New investors
Before issue
After issue Number of shares Number of
voting rights % of share
capital
% of voting rights Number of shares Number of
voting rights % of share
capital
% of voting rights Executive officers 272 727 522 727
1.14% 1.80% 322 731 572 731 0.78%
1.23% Employees 250 000 500 000 1.05% 1.72% 250 000 500 000
0.61% 1.08% Other founders and consultants 683 333 1 365 666 2.86%
4.69% 683 333 1 365 666 1.66% 2.94% Treasury shares 85 535 - 0.36%
- 85 535 - 0.21% - Existing investors 11 196 153 15 279 950 46.85%
52.49% 12 446 149 16 529 946 30.16% 35.57% o/w Idinvest 2 731 655 2
918 023 11.43% 10.02% 3 981 651 4 168 019 9.65% 8.97% New investors
- - - - 14 437 500 14 437 500 34.98% 31.06% o/w Kisco Co - - - - 3
750 000 3 750 000 9.09% 8.07% Free float 11 411 929 11 439 640
47.75% 39.30% 13 042 774 13 070 485 31.61% 28.12%
Total
23 899 677 29 107 983
100% 100% 41 268 022
46 476 328 100% 100%
LCM
MIDCAP
LOUIS CAPITAL MARKETS
PARTNERS
Lead Manager and Bookrunner
Advisor to the Company
Information available to investors
Copies of the prospectus bearing the visa of the Autorité des
marchés financiers (the “AMF”) on June 11, 2018 under no.
18-235 (the “Prospectus”), consisting of the Registration Document
filed on June 11, 2018 under no. R.18-050 and a
Securities Note (including the Summary Prospectus), may be obtained
free of charge from Safe Orthopaedics (Allée Rosa Luxemburg, Parc
des Bellevues, Bâtiment le Californie, 95610 Eragny-Sur-Oise), or
by downloading it from the Safe Orthopaedics (www.SafeOrtho.com)
Autorité des marchés financiers (www.amf-france.org) websites.
Safe Orthopaedics draws investors’ attention to the risk
factors presented in chapter 4 of the Registration Document and in
Chapter 2 of the Securities Note.
Key upcoming dates in the financial calendar
- Second-quarter 2018 revenues: July 10,
2018 (after the market closes)
About Safe Orthopaedics
Founded in 2010, Safe Orthopaedics is a French medical
technology company that offers the safest technologies to treat
spinal fracture. Delivered sterile, all implants and
respective disposable instrumentation are available to the surgeon
at any time, any place. These technologies enable minimally
invasive approaches, reducing risks of cross contamination and
infection in the interest of the patient. Protected by 17 patent
families, the SteriSpine™ Kits are CE marked and FDA cleared. The
company is based at Eragny-Sur-Oise (France), and has 37
employees.
For more information, visit: www.SafeOrtho.com
Note
This press release does not constitute, and may not be
considered as constituting, an offer to the public, an offer for
sale or subscription, or a solicitation of a purchase or
subscription order, or as being intended to solicit the public’s
interest in view of a public offering.
This press release is a promotional communication and not a
prospectus within the meaning of Directive 2003/71/EC of the
European Parliament and of the Council of 4 November 2003 as
modified, particularly by Directive 2010/73/EU of the European
Parliament and of the Council of 24 November 2010, as modified and
as transposed in each of the Member States of the European Economic
Area (the “Prospectus Directive”).
Regarding the Member States of the European Economic Area other
than France (the “Member States”) that have transposed the
Prospectus Directive, no action has been undertaken or will be
undertaken to allow a public offer of the securities that are the
subject of this press release necessitating the publication of a
prospectus in any one of the Member States. Consequently, the
subject securities may be offered in the Member States solely: (a)
to legal entities that are qualified investors as defined in the
Prospectus Directive; or (b) in the other cases that do not
necessitate the publication by the Company of a prospectus in
respect of Article 3(2) of the Prospective Directive and/or of the
regulations applicable in that Member State and on the condition
that such an offer does not require the publication by the Company
of a prospectus under the provisions of Article 3 of the Prospectus
Directive or of a supplement to the prospects under the provisions
of Article 16 of the Prospectus Directive.
This press release and the information it contains is addressed
to and intended solely for persons (i) who are located outside the
United Kingdom, (ii) who are investment professionals within the
meaning of Article 19(5) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005 (the “Financial Promotion
Order”) or (iii) who are referred to by Article 49(2) (a) to (d) of
the Financial Promotion Order (high net worth companies,
unincorporated associations etc.) or (iv) to whom an invitation or
inducement to engage in investment activity (within the meaning of
Article 21 of the Financial Services and Markets Act 2000) can be
legally communicated or transmitted (the persons referred to in
paragraphs (i), (ii), (iii) and (iv) being referred to together as
“Authorized Persons”). Any invitation, offer or agreement in view
of the subscription or purchase of the securities that are the
subject of this press release shall be accessible solely to
Authorized Persons and may be carried out solely by Authorized
Persons. This press release is addressed solely to Authorized
Persons and may not be used by any person other than an Authorized
Person. This press release and the information contained herein do
not constitute an offer to purchase or subscribe securities or any
solicitation whatsoever to purchase or subscribe securities nor any
solicitation whatsoever to sell securities in the United States of
America or in any other jurisdiction in which the transaction may
be subject to restrictions. The subject securities neither have
been nor will be registered within the meaning of the U.S.
Securities Act of 1933, as modified (the “U.S. Securities Act”),
and may not be offered or sold in the United States of America
without registration or exemption from the registration requirement
pursuant to the U.S. Securities Act, and the Company does not have
the intention to make any public offer of its securities in the
United States of America.
The dissemination of this press release may, in certain
countries, be subject to specific regulations. Persons in
possession of this press release are responsible for finding out
about and complying with any local restrictions.
This press release must not be published, transmitted or
distributed, directly or indirectly, within the territory of the
United States of America, Canada, Australia or Japan.
THE INFORMATION CONTAINED HEREIN IS NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, CANADA, AUSTRALIA, OR JAPAN.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180703005630/en/
Safe OrthopaedicsFrançois-Henri Reynaud, +33 (0)1 34 21
50 00CFOinvestors@safeorthopaedics.comorRelations
InvestisseursNewCapJulien Perez / Valentine Brouchot,
+33 (0)1 44 71 94 94SafeOrtho@newcap.euorRelations
PresseUlysse CommunicationBruno Arabian, +33 (0)6 87 88
47 26barabian@ulysse-communication.comorNicolas Daniels, +33 (0)6
63 66 59 22ndaniels@ulysse-communication.com